Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Immune Cell Blood Test May Predict Melanoma Immunotherapy Response

By LabMedica International staff writers
Posted on 12 Aug 2026

Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. More...

Immunotherapy has extended survival for many patients with advanced melanoma, but nearly half do not respond, while others develop serious adverse effects. This variability leaves clinicians without reliable predictors of treatment benefit or toxicity. Noninvasive blood-based monitoring could therefore provide a valuable way to guide treatment decisions and ongoing surveillance. A new study shows that coordinated changes in circulating B and T lymphocytes during immunotherapy are associated with both survival outcomes and treatment-related side effects.

Researchers at King’s College London analyzed circulating B and T lymphocytes to better characterize adaptive immune responses during checkpoint inhibitor therapy. Using mass cytometry, which measures multiple characteristics of individual immune cells simultaneously, the team was able to identify distinct and rare immune cell subsets and track how they changed during treatment. This approach enabled a detailed, simultaneous assessment of B- and T-cell dynamics in the peripheral blood of melanoma patients, providing a broader view of how the adaptive immune system responds to immunotherapy.

The study included blood samples from 24 patients with stage 2–4 melanoma who were treated at Guy’s and St Thomas’ NHS Foundation Trust, along with samples from 25 healthy volunteers. Blood was collected before treatment and at two additional time points during therapy, allowing the researchers to follow changes in immune cell populations over time. Early immune reinvigoration, characterized by renewed activation and expansion of both B and T cells within the first six weeks of treatment, was associated with favorable clinical outcomes, including longer survival.

In contrast, patients who developed immature or poorly functioning B-cell populations during treatment experienced poorer outcomes. A lower pretreatment capacity of both B and T cells to mount anticancer responses was also associated with reduced survival, suggesting that immune status before therapy may influence subsequent treatment benefit. Certain T-cell subsets were additionally linked to treatment-related side effects, while substantial differences in immune cell levels between individual patients may help explain why responses to immunotherapy vary so widely.

Published in the Journal for ImmunoTherapy of Cancer on August 7, 2026, the findings highlight the potential of blood-based immune profiling to provide a more comprehensive picture of how patients respond to immunotherapy. Such profiling could help identify patients who are more likely to benefit from treatment, those at greater risk of toxicity, and individuals who may require closer monitoring during therapy. The researchers now plan to examine B and T cells within tumors and to validate the approach in larger patient cohorts and in other cancers, including triple-negative breast cancer.

“B cells have emerged as critical contributors to survival and treatment outcomes in melanoma. In-depth studies of these cells may provide important insights to help address the current clinical challenges in melanoma treatment. Studying immune cells from patients' blood samples is much less invasive than biopsies,” said Lucy Booth, Ph.D. student at St. John’s Institute of Dermatology, King’s College London.

Related Links
King’s College London


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Urine Analyzer
respons® UDS100
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.